ArticleACS infectious diseases2018
The Importance of Collaboration between Industry, Academics, and Nonprofits in Tropical Disease Drug Discovery.
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A comprehensive review of thermal ablation technologies for transdermal drug delivery: mechanisms, commercial products, and future smart systems.Drug delivery and translational research · 2026Review
- Applications of virus-like particles in the prevention of protozoan parasite infection.Nanomedicine (London, England) · 2025Review
- Rehabilitation Engineering Research Center on Mobile Rehabilitation: State of the Science Conference Report-Future Directions for mRehab for People with Disabilities.International journal of environmental research and public health · 2025Article
- The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.Molecular therapy. Nucleic acids · 2024Review
- Small-Molecule Antibiotic Drug Development: Need and Challenges.ACS infectious diseases · 2023Review
- Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases.PLoS neglected tropical diseases · 2023Article
- An Updated View of theACS infectious diseases · 2022Review
- Identification of β-Lactams Active againstACS infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Collaborations between academic, industrial, and nonprofit companies can provide sufficient impetus to propel projects that have little economic return; such projects are prevalent in tropical disease drug discovery. In these collaborations, each partner contributes a unique set of skills and technical expertise which is advantageous to the project as a whole. Highly product-focused processes and specialized expertise sets dominate industry groups. When coupled with the strategic guidance from public-private partnerships and the academic tendency to work on high-risk projects with low financial rewards, a powerful combination results. There are numerous examples throughout the literature about these collaborative efforts to combat a variety of tropical diseases (including leishmaniasis, Chagas disease, African sleeping sickness, and malaria), from all stages of the drug discovery process to the advancement of new drugs into the clinic. However, there is still uncertainty from many academic institutions as to how to establish and engage in these research consortiums. This Viewpoint highlights opportunities, benefits, and suggestions for productive collaborations in this disease space.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.